GRI GRI Bio
- 0.315
- -0.003-0.94%
GRI Bio News
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect
FRENCHTOWN, NJ / ACCESSWIRE / May 23, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced that Marc Hertz, PhD, Chief Executive Officer of
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment Highlighting Positive Preclinical Data From Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on AutoimmunityCompany reiterates 2024 as year of data Click here to watch th
GRI Bio Presents Positive Preclinical Data From Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
Data presented at the 14th International Congress on AutoimmunityEncouraging preclinical data observed to date on par with OFEV (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sa
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ETLA JOLLA, CA, May 14, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative p
GRI Bio Shares Informational Disclosure Under Regulation FD
GRI Bio: Runway To Fund Operating Expenses, Capital Spending Needs Into 3Q >GRI
GRI Bio: Runway To Fund Operating Expenses, Capital Spending Needs Into 3Q >GRI
GRI Bio Q1 EPS $(0.46) Up From $(37.31) YoY
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(0.46) per share. This is a 98.77 percent increase over losses of $(37.31) per share from the same period last year.
GRI Bio 1Q Loss $1.9M >GRI
GRI Bio 1Q Loss $1.9M >GRI
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 Ongoin
GRI Bio Files for $75M Mixed Shelf
GRI Bio | 10-Q: Quarterly report
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go u
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
LA JOLLA, CA, April 29, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the tre
GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments
GRI Bio (GRI) said Tuesday South Korea's Korean Intellectual Property Office has granted a patent for liver inflammatory condition treatments. The patent covers compositions and methods for modulating
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators With Issuance of Korea Patent
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovationContinued advancement of an innovative pipeline of NKT cell modulato
12 Health Care Stocks Moving In Monday's After-Market Session
GainersKineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stoc
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
LA JOLLA, CA, April 08, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the t
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas
GRI Bio Reports FY Results
Analysis
Price Target
No Data
